Medication Compliance and Adherence in Schizophrenia: Raising the Bar - Boston

Medication Compliance and Adherence in Schizophrenia: Raising the Bar
1 AMA PRA Category 1 Credit(s)
Launch Date:
May 07, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Primary Care Physicians, Psychiatrists

Relevant Terms:

Patient Adherence, Patient Compliance, Schizophrenia

John Lauriello, MD

John Lauriello, MD
Professor and Chair, Department of Psychiatry
University of Missouri School of Medicine
Columbia, MO

In June 2009, Dr. Lauriello became only the third permanent chair of the University of Missouri Department of Psychiatry in its 50 year history. Dr. Lauriello holds the University of Missouri Chancellor's Chair of Excellence in Psychiatry. During his leadership he has overseen the opening of the University of Missouri Psychiatric Center. Formerly an acute care state facility, it is widely regarded as the psychiatric center of excellence for the mid Missouri region.

Prior to coming to the University of Missouri, Dr. Lauriello was the clinical Vice Chair at the University of New Mexico and Executive Medical Director of the UNM Psychiatric Center. At UNM he directed the Schizophrenia Research Group, which focused on clinical trials and neuroimaging, and served as a UNM site principal investigator for the Mental Illness and Neuroscience Discovery (MIND) Institute, a consortium of universities, schools of medicine, brain research institutions and laboratories in Minnesota, Massachusetts and New Mexico.  

Dr. Lauriello remains an active expert and investigator in the area of diagnosis and treatment of schizophrenia. He is an author of over 80 publications and is a frequent presenter at national meetings. His recent awards include the 2011 Drs. M. Page and Henry Laughlin Alumnus of the Year Award, the highest alumni honor presented by the Temple University School of Medicine, and had been voted one of the Best Doctors in America® from 1998 to 2013.

A graduate of Yale University in New Haven, Connecticut, Dr. Lauriello completed medical school at Temple University in Philadelphia and residency at New York Presbyterian Hospital's Payne Whitney Psychiatric Clinic. He completed fellowships focused on psychopharmacology and psychobiology at the University of California San Diego and Stanford University.

Christoph U. Correll, MD

Christoph U. Correll, MD
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital
Investigator, Feinstein Institute for Medical Research
Associate Professor of Psychiatry
Hofstra North Shore LIJ School of Medicine
Adjunct Associate Professor of Psychiatry
Albert Einstein College of Medicine
Glen Oaks, NY

Christoph U. Correll, MD, is professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) Program at the Zucker Hillside Hospital, both in New York. He is further the director of the Adverse Events Unit and the Core Laboratory Unit at the Zucker Hillside Hospital Advanced Center for Intervention and Services Research. 
Professor Correll completed his medical studies at the Free University of Berlin and Dundee University Medical School in Scotland. He is a board certified general psychiatrist and child and adolescent psychiatrist, having trained at The Zucker Hillside Hospital in Queens, New York.
Professor Correll's research and clinical work focus on the identification, characterization and treatment of adults and youth with severe psychiatric disorders. His areas of expertise include severe psychotic and mood disorders, including schizophrenia, bipolar disorder, major depression, as well as aggressive spectrum disorders, including the prodrome, first episode, multi-episode and refractory illness phase. He further focuses on the risk-benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.
Professor Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of nine scientific journals. He is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.

Alejandro (Alex) Kopelowicz, MD

Alejandro (Alex) Kopelowicz, MD
Professor and Vice-Chair, Department of Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine at UCLA
Medical Director of the San Fernando Mental Health Center (SFMHC)
Chief of Psychiatry at Olive View
UCLA Medical Center
Los Angeles, CA

Alejandro (Alex) Kopelowicz, MD, is Professor and Vice-Chair in the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Medical Director of the San Fernando Mental Health Center (SFMHC), a community mental health center operated by the Department of Mental Health of Los Angeles County and Chief of Psychiatry at Olive View-UCLA Medical Center. Dr. Kopelowicz has been a frequent lecturer on biobehavioral treatment and psychiatric rehabilitation techniques. He has written a number of articles and book chapters on these subjects.

Dr. Kopelowicz has been the recipient of several grants from the National Institute of Mental Health, including current projects that focus on culturally adapting the family psychoeducation approach for a Mexican-American population and a multi-site study comparing a long-acting, injectable antipsychotic medication with oral atypical antipsychotic agents.

Dr. Kopelowicz was born in Buenos Aires, Argentina and immigrated with his family to New York City at a young age. He graduated Haverford College with a B.A. in Psychology, and went on to receive his medical education at Rutgers Medical School in New Jersey. He completed his psychiatric residency at UCLA.

Peter Weiden, MD

Peter Weiden, MD
Professor of Psychiatry and Director of the Psychotic Disorders Program
Center for Cognitive Medicine
University of Illinois Medical Center
Chicago, IL

Dr. Peter J. Weiden is Professor of Psychiatry and Director of the Psychosis Program at the University of Illinois Medical Center in Chicago.
Known for his work on patient and family education addressing the treatment of psychosis, much of Dr. Weiden's career has focused on improving clinical outcomes for patients with schizophrenia. His research has focused on bridging psychopharmacology and public health issues in the treatment of schizophrenia, and he has a particular interest in the use of cognitive behavioral therapy (CBT)–type interventions for individuals with psychotic disorders.
A frequent contributor to the medical literature, Dr. Weiden has authored or coauthored more than 150 journal articles as well as a number of books and practice guidelines. He has published extensively on the problem of nonadherence with antipsychotic medications. He serves on the editorial board of Clinical Psychiatry News and is a contributing editor for Journal of Practical Psychiatry and Behavioral Health. He is also a reviewer for a number of peer-reviewed publications.
Dr. Weiden has received several awards from advocacy groups and was named an Exemplary Psychiatrist on three separate occasions by the National Alliance on Mental Illness (NAMI). Dr. Weiden's book, Breakthroughs in Antipsychotic Medications: A Guide for Patients, Families, and Clinicians (WW Norton & Co.), received the Ken Johnson Memorial Book Award in 2000 as one of the most outstanding books in mental health. For his research on relapse prevention, he received NAMI's Judith Silver Young Scientist Award in 1996. He has been listed in the "Best Doctors in New York" issue of New York Magazine.
Active in many professional associations, Dr. Weiden is a member of the American Psychiatric Association, the International CBT for Psychosis Working Group, and the Academy of Cognitive Therapy. He also serves on NAMI's Scientific Advisory Board.
Dr. Weiden earned his BA in Chemistry from Swarthmore College in Pennsylvania and his MD from the State University of New York at Stony Brook. He completed his psychiatric residency at the Payne Whitney Clinic–New York Hospital and a psychiatric epidemiology fellowship at the Mailman School of Public Health of Columbia University in New York City.
1. Integrate evidence-based interventions for improved schizophrenia treatment adherence and compliance into daily practice
2. Discuss efficacy, safety and PK data for long-acting injectable antipsychotics (LAI) for schizophrenia
3. Select eligible patients for LAI intervention, and begin the dialog regarding LAI use

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty Disclosures
John Lauriello, MD, has affiliations with Otsuka and Janssen (advisory board, payment made to the University of Missouri-contract to the Department of Psychiatry).
Christoph U Correll, MD, has affiliations with Actelion, Alexza, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck,
Janssen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda (advisory board); BMS, Merck, and Otsuka (fees for non-CME/CE services received directly from a commercial interest or their agents); BMS, Janssen/J&J, National Institute of Mental Health (NIMH), and Otsuka (contracted research).
Alejandro (Alex) Kopelowicz, MD, has no affiliations with commercial interests to disclose.
Peter Weiden, MD, has affiliations with Delpor, Johnson & Johnson (Janssen), Lundbeck, Otsuka USA, Merck, Novartis, Sunovion, and Genentech/Roche (consultant); Johnson & Johnson (Janssen), Merck, Novartis, and Sunovion (speakers bureau); Genentech/Roche, Johnson & Johnson (Janssen), NIMH, Novartis, Sunovion, and Neurocrine (grant support); Delpor (stockholder).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
Cynthia M. Kunzer has no affiliations with commercial interests to disclose.
Lora Rhodes, MSW, has no affiliations with commerical interests to disclose

Postgraduate Institute for Medicine
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content: Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated time to complete-1 hour

There is no fee for this educational activity.

This activity is jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine. RMEI gratefully acknowledges an educational grant from Otsuka in support of this CME activity.

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credits™. A statement of credit will be emailed to you and also will be available to print from your user history page.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must complete the post-test and evaluation to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.